Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab.

Literature DB >> 20688807

Bevacizumab.

Filis Kazazi-Hyseni¹, Jos H Beijnen, Jan H M Schellens.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20688807 PMCID： PMC3228024 DOI： 10.1634/theoncologist.2009-0317

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

× No keyword cloud information.

40 in total

Review 1. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Authors: Ted Shih; Celeste Lindley
Journal: Clin Ther Date: 2006-11 Impact factor: 3.393

2. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

Authors: Hedy Lee Kindler; Donna Niedzwiecki; Donna Hollis; Susan Sutherland; Deborah Schrag; Herbert Hurwitz; Federico Innocenti; Mary Frances Mulcahy; Eileen O'Reilly; Timothy F Wozniak; Joel Picus; Pankaj Bhargava; Robert J Mayer; Richard L Schilsky; Richard M Goldberg
Journal: J Clin Oncol Date: 2010-07-06 Impact factor: 44.544

3. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors: David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544

4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245

5. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors: Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544

Review 6. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Authors: Shobha Rani Nalluri; David Chu; Roger Keresztes; Xiaolei Zhu; Shenhong Wu
Journal: JAMA Date: 2008-11-19 Impact factor: 56.272

7. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

Authors: Fairooz F Kabbinavar; Herbert I Hurwitz; Jing Yi; Somnath Sarkar; Oliver Rosen
Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544

8. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Authors: Eric Van Cutsem; Walter L Vervenne; Jaafar Bennouna; Yves Humblet; Sharlene Gill; Jean-Luc Van Laethem; Chris Verslype; Werner Scheithauer; Aijing Shang; Jan Cosaert; Malcolm J Moore
Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544

Review 9. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Authors: P Tappenden; R Jones; S Paisley; C Carroll
Journal: Health Technol Assess Date: 2007-03 Impact factor: 4.014

10. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.

Authors: R Torrisi; V Bagnardi; A Cardillo; F Bertolini; E Scarano; L Orlando; P Mancuso; A Luini; A Calleri; G Viale; A Goldhirsch; M Colleoni
Journal: Br J Cancer Date: 2008-10-21 Impact factor: 7.640

50 in total

Review 1. Targeted therapies for gastric cancer: current status.

Authors: Jaclyn Yoong; Michael Michael; Trevor Leong
Journal: Drugs Date: 2011-07-30 Impact factor: 9.546

2. Do bevacizumab solutions interact with silicone or polyurethane catheters during an infusion through implantable venous access ports?

Authors: Nicolas Tokhadzé; Philip Chennell; Régis Cueff; Valérie Sautou
Journal: J R Soc Interface Date: 2019-09-25 Impact factor: 4.118

Review 3. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.

Authors: Arijit Nath; Soham Mitra; Tanuma Mistry; Ranita Pal; Vilas D Nasare
Journal: Med Oncol Date: 2021-11-23 Impact factor: 3.064

4. Ramucirumab for the treatment of gastroesophageal cancers.

Authors: Y Shimodaira; E Elimova; R Wadhwa; H Shiozaki; N Charalampakis; V Planjery; J E Rogers; S Song; J A Ajani
Journal: Expert Opin Orphan Drugs Date: 2015-05-25 Impact factor: 0.694

Review 5. Chemical and Radiation-Associated Jaw Lesions.

Authors: Temitope T Omolehinwa; Sunday O Akintoye
Journal: Dent Clin North Am Date: 2016-01

Review 6. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

Authors: Megan Li; Deanna L Kroetz
Journal: Pharmacol Ther Date: 2017-09-04 Impact factor: 12.310

Review 7. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors: Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal: Curr Oncol Rep Date: 2013-06 Impact factor: 5.075